Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
Trial details
- Registry ID
- NCT02017912
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as NurOwn
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSNCT02017912 | Brainstorm-Cell Therapeutics | Phase 2 | Completed | 2016-03Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |